Medline: A Lack Of Compelling Risk-Reward Makes Me Cautious
Summarize this article with:
The Value InvestorInvesting Group LeaderFollow5ShareSavePlay(8min)CommentsSummaryMedline delivered strong Q4 momentum and 2025 sales growth, but recent margin pressure has left profits largely flat.Medline guides for 8-9% organic sales growth and modest adjusted EBITDA gains in 2026, yet margin compression remains a material concern.Selling shareholders, including Blackstone and Carlyle, recently offloaded a significant stake post lock-up, highlighting valuation sensitivity.At $44 per share, Medline trades at 31-33x forward earnings, a demanding multiple given segment margin discrepancies and leverage.Looking for more investing ideas like this one? Get them exclusively at Value In Corporate Events. Learn More » MTStock Studio/E+ via Getty Images In an uncertain external environment, shares of Medline (MDLN) have seen a solid first quarter. This came despite selling shareholders offering more shares early in March. Investors are still buying into the long-term growth story, with MedlineThis article was written byThe Value Investor27.73K FollowersFollowThe Value Investor has a Master of Science with specialization in financial markets and a decade of experience tracking companies via catalytic company events. As the leader of the investing group Value In Corporate Events they provide members with opportunities to capitalize on IPOs, mergers & acquisitions, earnings reports and changes in corporate capital allocation. Coverage includes 10 major events a month with an eye towards finding the best opportunities. Learn more.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.